

Fig. 1A

Mouse
Human

MSSIGTGYDL SASTFSPDGR VFQVEYAMKA VENSSTAIGI RCKDGVVEGV
EKLVLKLYE EGSNKRLFNV DRHVGNAVAG LLADARSLAD IAREASNFR
SNFGYNIPLK HLADRVAMV HAYTLYSAVR PFGCSFMIGS YSANDGAOLY
MIDPSGVSYG YWCAIGKAR QAKTEIEKL QMKEMTCRDV VKEVAKIYYI
VHDEVKOKAF EELSWGEL TKGRHEIVPK DIREAEKYA KESLKEDES
DDNNM

Fig. 1C

$\alpha 7$ subunit

Growth/LacZ+




Fig. 1D

PR39 IP.

$\alpha 7$



Fig. 1B

C terminal tails
Net Charge

Sequence	Net Charge
$\alpha 1$ AERD	-1
$\alpha 2$ A	0
$\alpha 3$ KKHEEEAKAREKEKEKEDK	+1
$\alpha 4$ EKEKEENKKKOKKAS	+2
$\alpha 5$	0
$\alpha 6$ EEPQKKAQPADEPAEKADPEMEH	-3
$\alpha 7$ AKESLKEEDSDDNM	-6

09276868.032699

Fig. 2A

ECV

ECV-E4

ECV-PR39

ECV Lactacystin

I- κ B

Fig. 2C

Control

PR39 10nM

MG132 10 μ M

Lactacystin 10 μ M

Fig. 2B

TNF- α

Control

Control


PR39 10nM

MG132 10 μ M

Lactacystin 10 μ M

Fig. 2D

Luciferase Activity



04276868-032699

Fig. 4A




Fig. 4B





Fig. 4C



Control

PR 39

Fig. 5A





Fig. 5C

Fig. 5B





Fig. 6




Fig. 7

09276858.032599